脛骨遠端骨折為幹細胞基礎的治療安全和有效的

jack1381818

從耶路撒冷的研究人員發現，一種微創幹細胞為基礎的治療癒合時間下降，在脛骨遠端骨折的患者，並沒有產生並發症，根據最近公佈的初步研究結果。
0 ?2 B  \, R  Q
/ I$ R) R+ ]2 N# h  G“研究表明，包括新鮮分離的自體複合移植[ 骨髓間充質幹細胞，間充質幹細胞混合[ 富血小板血漿 PRP和脫鈣骨基質（DBM）是安全的脛骨遠端骨折的早期管理，“ 梅厄Liebergall，醫學博士，在耶路撒冷哈達薩醫療中心，和他的同事在他們的研究中寫道。 “進一步的調查和系統的優化可能會產生更好的結果。”
# @9 L. u* T; Q% W: h" g, P) y( S- A$ ?: e' `+ V$ u% }! q7 M3 F
Researchers from Jerusalem found that a minimally invasive stem cell-based therapy decreased time to union and produced no complications in patients with distal tibia fractures, according to the results of a recently published preliminary study.; C1 @" x7 D0 M. r8 {

1 I) l- G0 m# P5 C4 `“Our study shows that a composite graft comprised of freshly isolated autologous [mesenchymal stem cells] MSCs mixed with [platelet-rich plasma] PRP and demineralized bone matrix (DBM) is safe in the early management of fractures of the distal tibia,” Meir Liebergall, MD, from the Hadassah Medical Center in Jerusalem, and colleagues wrote in their study. “Further investigation and optimization of the system may yield even better results.”4 h" M. p$ N5 q+ J
! v) i- i; ^* @9 s7 A; u
Meir Liebergall( W  `! l( x- V6 D% {0 F
! n. ?8 j1 I2 V8 M
In their prospective trial, Liebergall and colleagues randomized 24 patients who had operative treatment for a distal tibial fracture. The intervention group received a fluoroscopic-delivered composite graft with PRP, sorted MSCs in suspension and DBM, and was compared to a control group who received no treatment. All patients were followed up at 2 weeks, 6 weeks, 3 months, 6 months, 9 months and 12 months.
# p  m! z. H( K/ y7 ~
: c" b3 _, U3 F! `8 O$ BThe investigators found no complications in either group. At 12-month follow-up, they saw no significant differences between the groups regarding pain or quality of life measures. There were no delayed unions in the intervention group. The investigators found that the fractures of three patients in the control group did not unite by 3-month follow-up.
3 C1 j2 X3 D3 B! M& [+ b$ Q; J
- P+ }+ l4 b/ ?' ?: E4 h) s# L- q“Future applications of freshly isolated MSCs may include delivery with active signal molecules and transient or permanent genetic and functional modifications of the cells,” Liebergall and colleagues wrote. “This graft, in turn, may be applied preventively in cases where difficulties in fracture healing are foreseen.”" ~+ ~% Y% K! G0 n+ I! |* R' d
  L. p/ t7 {  C
Disclosure: The authors have no relevant financial disclosures.